



The relative strengths and weaknesses of Genomic Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genomic Health INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Genomic Health INC is the variable Selling and Marketing Expense, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 91% points above the market average of 148%.

Input Variable	Value in 1000 USD
Assets, Current	174,260
Assets, Non-Current	10,917
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	72,670
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	39,516
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-1,492
Other Expenses	56,222
Other Liabilities	0
Other Net Income	4,097
Other Revenues	340,750
Property Plant and Equipment	46,440
Research And Development Expense	62,811
Selling and Marketing Expense	157,001

Output Variable	Value in 1000 USD
Assets	231,617
Liabilities	39,516
Expenses	348,704
Revenues	340,750
Stockholders Equity	192,101
Net Income	-3,857
Comprehensive Net Income	-5,349
BaseVar	483,088
ECR before LimitedLiability	202%
Economic Capital Ratio	239%